{"DataElement":{"publicId":"2682793","version":"1","preferredName":"Chronic Myelogenous Leukemia Transplantation Time Chronic Phase Cytogenetic Analysis Remission Ind-3","preferredDefinition":"The indicator that describes whether or not the type of chronic phase achieved at the time of transplant for chronic myelogenous leukemia was a cytogenetic remission.","longName":"CML_CP_CYT_RM_IND3","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2682791","version":"1","preferredName":"Chronic Myelogenous Leukemia Transplantation Time Chronic Phase","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._The grafting of tissues from one individual to another or place to place within a single individual._The continuum of experience in which events pass from the future through the present to the past._A phase of chronic myelogenous leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)","longName":"CML_CP_TRN","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2500393","version":"1","preferredName":"CML","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","longName":"C3174","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995DB3E-65B1-6546-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2682789","version":"1","preferredName":"Transplantation Time Chronic Phase Chronic Myelogenous Leukemia","preferredDefinition":"The grafting of tissues from one individual to another or place to place within a single individual.:the continuum of experience in which events pass from the future through the present to the past.:A phase of chronic myelogenous leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)","longName":"C15342:C25207:C3175","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3175","definition":"A phase of chronic myeloid leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6A1086-5074-2C8B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ONEDATA","dateModified":"2007-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6A1086-5085-2C8B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2682780","version":"1","preferredName":"Chronic Myelogenous Leukemia Cytogenetic Analysis Remission Ind-3","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._An abatement in intensity or degree (as in the manifestations of a disease)._A caDSR representation term that is used to indicate a question with permissible values of yes/no/unknown._","longName":"CML_CYT_RM_IND3","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cytogenetics Unknown","valueDescription":"Cytogenetics Unknown","ValueMeaning":{"publicId":"2682781","version":"1","preferredName":"Cytogenetics Unknown","longName":"2682781","preferredDefinition":"Cytogenetics is the study of chromosomes and the related disease states caused by numerical and structural chromosome abnormalities.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetics","conceptCode":"C16487","definition":"The branch of biology that studies the cellular aspects of heredity, especially the chromosomes. Includes the study of disease states caused by numerical and structural chromosome abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A68BBB0-DAC8-1FE5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A68BBB0-DAE1-1FE5-E044-0003BA3F9857","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ALEYR","dateModified":"2007-09-18","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A68BBB0-DAED-1FE5-E044-0003BA3F9857","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ALEYR","dateModified":"2007-09-18","deletedIndicator":"No"},{"value":"Complete","valueDescription":"Complete","ValueMeaning":{"publicId":"2566649","version":"1","preferredName":"Complete","longName":"2566649","preferredDefinition":"Complete; having every necessary or normal part or component or step; or having come or been brought to a conclusion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D166-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-13","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-13","modifiedBy":"COOPERM","dateModified":"2008-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A68BBB0-DAF9-1FE5-E044-0003BA3F9857","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ALEYR","dateModified":"2007-09-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2716631","version":"1","preferredName":"CML Cytogenetic Analysis Remission Ind-3","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003:Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.:An abatement in intensity or degree (as in the manifestations of a disease).:A caDSR representation term that is used to indicate a question with permissible values of yes/no/unknown.","longName":"C3174:C18280:C18246:C38148","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Yes, No, or Unknown Response","conceptCode":"C38148","definition":"A response or indicator that can have a value of yes, no, or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41CC9658-5398-0D3C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-12-21","modifiedBy":"ONEDATA","dateModified":"2007-12-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A689FF0-4328-1816-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"REEVESD","dateModified":"2014-08-17","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"pre_ted_cml_cr_cp_cyto_rm","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"At the time of transplantatio","type":"Preferred Question Text","description":"At the time of transplantation, was the type of chronic phase of the chronic myelogenous leukemia also a cytogenetic remission?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6A24BA-7416-3342-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"KUMMEROA","dateModified":"2021-04-30","changeDescription":". 2021-4-30 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}